Mineralys Therapeutics(US:MLYS)2025-11-10 21:06Financial Performance - Cash, cash equivalents, and investments increased to $593.6 million as of September 30, 2025, up from $198.2 million as of December 31, 2024[4] - The net loss for Q3 2025 was $36.9 million, a reduction from $56.3 million in Q3 2024[8] - Total other income, net for Q3 2025 was $4.2 million, compared to $3.8 million in Q3 2024, attributed to increased interest earned on investments[7] Research and Development - Research and Development (R&D) expenses decreased to $31.5 million for Q3 2025, down from $54.0 million in Q3 2024, primarily due to the conclusion of the lorundrostat pivotal program[5] - The company has completed four successful clinical trials of lorundrostat, supporting its efficacy and safety profile[17] - The company completed enrollment in the Explore-OSA Phase 2 trial, with topline results expected in Q1 2026[3] Future Plans - The company plans to submit a New Drug Application (NDA) for lorundrostat by late 2025 or Q1 2026[1] - The company believes its current cash reserves will fund planned clinical trials and operations into 2028[4] - The company aims to evaluate lorundrostat's use in hypertension-related comorbidities, expanding its treatment opportunities[3] Administrative Expenses - General and Administrative (G&A) expenses rose to $9.7 million in Q3 2025, compared to $6.1 million in Q3 2024, driven by higher compensation and professional fees[6]